dalteparin has been researched along with Metabolic Syndrome in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chazova, IE | 1 |
| Mychka, VB | 1 |
| Mamyrbaeva, KM | 1 |
| Gornostaev, VV | 1 |
| Dvoskina, IM | 1 |
| Sergienko, VB | 1 |
1 other study available for dalteparin and Metabolic Syndrome
| Article | Year |
|---|---|
[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk].
Topics: Adult; Anticoagulants; Blood Glucose; Blood Pressure; Body Mass Index; Brain; C-Peptide; Cardiovascu | 2004 |